Research Paper Volume 15, Issue 16 pp 8444—8457
m6A methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression
Figure 1. Expression of METTL16 and PD-L1 in clinical samples and cell lines of CRC. CRC tumor and non-tumor tissues were collected from patient with CRC. The RNA levels of (A) PD-L1 and (B) METTL16 were measured by qPCR assay. (C) The protein expression of PD-L1 and METTL16 was measured by IHC experiment. (D) The Pearson correlation analysis of PD-L1 and METTL16 in tumor tissues (n=20). (E) The RNA level of METTl16 in CRC cell lines (NCM460, RKO, HCT116, SW480, Colo320, DLD-1, HCE8693, SW620, and HT29) and normal human colon epithelial cell line FHC was measured by qPCR. *p<0.05, **p<0.01, ***p<0.001.